José Baltar, Manuel Praga, Jorge Rojas-Rivera, Raquel Alegre, Sergio Barroso, Santiago Rodríguez de Córdoba, Gema Fernández-Juárez, Manuel Macías, Teresa Olea, Begoña Rivas, Alfonso Pobes, Francisco Martín, Miguel Blasco, Katia López-Revuelta, Miguel Angel Frutos, Gema Ariceta, José María Campistol, Cristina Rabasco, Ana Ávila, Alberto de Lorenzo, F. González, Sandra Elías, Elena Román, Manuel López-Mendoza, Santiago Mendizábal, Carmen Bernis, Virginia Cabello, Mario Espinosa, Teresa Cavero, Montserrat Diaz, and Monserrat Antón
C3 glomerulonephritis is a clinicopathologic entity defined by the presence of isolated or dominant deposits of C3 on immunofluorescence. To explore the effect of immunosuppression on C3 glomerulonephritis, we studied a series of 60 patients in whom a complete registry of treatments was available over a median follow-up of 47 months. Twenty patients had not received immunosuppressive treatments. In the remaining 40 patients, 22 had been treated with corticosteroids plus mycophenolate mofetil while 18 were treated with other immunosuppressive regimens (corticosteroids alone or corticosteroids plus cyclophosphamide). The number of patients developing end-stage renal disease was significantly lower among treated compared with untreated patients (3 vs. 7 patients, respectively). No patient in the corticosteroids plus mycophenolate mofetil group doubled serum creatinine nor developed end-stage renal disease, as compared with 7 (significant) and 3 (not significant), respectively, in patients treated with other immunosuppressive regimens. Renal survival (100, 80, and 72% at 5 years) and the number of patients achieving clinical remission (86, 50, and 25%) were significantly higher in patients treated with corticosteroids plus mycophenolate mofetil as compared with patients treated with other immunosuppressive regimens and untreated patients, respectively. Thus, immunosuppressive treatments, particularly corticosteroids plus mycophenolate mofetil, can be beneficial in C3 glomerulonephritis.